Quantification of risperidone and 9-hydroxyrisperidone in plasma and saliva from adult and pediatric patients by liquid chromatography–mass spectrometry

A robust and validated LC–MS–MS quantitative method, using column switching and mutiple reaction monitoring was developed for the analysis of risperidone (RIS) and 9-hydroxyrisperidone in human plasma and saliva. The analytical range was 1–100 ng/ml. The method used 25 μl of sample precipitated with...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Chromatography A 2004-02, Vol.1026 (1), p.175-183
Main Authors: Flarakos, J, Luo, W, Aman, M, Svinarov, D, Gerber, N, Vouros, P
Format: Article
Language:English
Subjects:
Adult
Analysis
Biological and medical sciences
Calibration
Chemical Precipitation
Child
Chromatography, Liquid
Column switching
General pharmacology
Humans
Hydroxyrisperidone
Isoxazoles - analysis
Isoxazoles - blood
Mass Spectrometry
Medical sciences
Molecular Structure
Paliperidone Palmitate
Pharmacology. Drug treatments
Pyrimidines - analysis
Pyrimidines - blood
Reproducibility of Results
Risperidone
Risperidone - analysis
Risperidone - blood
Saliva - chemistry
Sensitivity and Specificity
Validation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A robust and validated LC–MS–MS quantitative method, using column switching and mutiple reaction monitoring was developed for the analysis of risperidone (RIS) and 9-hydroxyrisperidone in human plasma and saliva. The analytical range was 1–100 ng/ml. The method used 25 μl of sample precipitated with 75 μl of acetonitrile containing internal standard (R068808). Analyses were conducted on a PE Sciex API-III+triple quadrupole mass spectrometer fitted with a Turbo IonSpray source. The method was validated for human plasma using EDTA as the anticoagulant and cross-validated to heparinized human plasma and saliva. The recoveries of risperidone and 9-hydroxyrisperidone were 90–93 and 89–93%, respectively. The validated method was applied to clinical samples to study risperidone and 9-hydroxyrisperidone concentrations in plasma and saliva. Risperidone and 9-hydroxyrisperidone appear in the saliva of patients treated with risperidone. Their detection/quantification in saliva provides evidence for recent adherence with therapy.
ISSN:0021-9673
DOI:10.1016/j.chroma.2003.10.138